I-Platinum-Resistant Ovarian Cancer therapy ithola ukwelashwa okuphumelelayo

I-InxMed Co., Ltd. imemezele ukuthi i-IN0018 inikezwe i-Breakthrough Therapy Designation yi-China National Medical Products Administration. Lokhu kuqokwa kusekelwe emiphumeleni yokuhlolwa komtholampilo kweSigaba Ib/II se-IN10018 somdlavuza weqanda omelana ne-platinum, nenkomba ehlongozwayo yokwelashwa komdlavuza we-ovarian ongazweli iplatinum kuhlanganiswe ne-PEG-liposomal doxorubicin. I-InxMed ihlela ukudalula idatha eyengeziwe ku-IN10018 eMhlanganweni Waminyaka Yonke we-American Society of Clinical Oncology ngoJuni 2022 futhi iqale isilingo esibalulekile engxenyeni yesibili yonyaka. 

I-Breakthrough Therapy Designation ihlose ukusiza izinkampani zisebenze eduze neziphathimandla ukuze kusheshiswe ucwaningo, ukuthuthukiswa, kanye nokugunyazwa kwezindlela zokwelapha ezintsha ezingabhekana nezidingo zezokwelapha ezingahlangatshezwana nazo. I-IN10018 ithole igama elisheshayo elivela ku-US Food and Drug Administration yokwelapha iziguli ezinomdlavuza wesibeletho ongamelana ne-platinum ngo-August 2021. I-InxMed izophila ngokuvumelana nokulindelwe okuphezulu futhi ilwela ukuletha izinzuzo zemithi emisha ezigulini ngokushesha okukhulu .

I-FAK iyi-non-receptor kinase ne-transmitter edlala indima ebalulekile ekunamatheleni kweseli, ukufuduka, kanye nokulawula. Ibonisa ukukhuphuka kokubonakaliswa kwezinhlobo eziningi zamathumba. Abacwaningi bathole ukuthi ukuvimbela indlela yokusayina ye-FAK kungahlehlisa ngempumelelo i-chemotherapy eyahluleka ngaphambilini kanye nokwelashwa okuhlosiwe okubangelwa ukumelana nomuthi futhi kuthuthukise impendulo nokusebenza ngempumelelo kwe-immunotherapy kumathumba aqinile.

I-IN10018 iyi-adenosine triphosphate FAK inhibitor enamandla futhi ekhetha kakhulu, futhi i-InxMed inamalungelo ayo okuthuthukisa umhlaba wonke kanye namalungelo okusebenza kwezohwebo. I-InxMed Nanjing Translational Medicine Center yenze ucwaningo olunzulu lwangempela lokuhlola kokuhlosiwe kwe-IN10018 kanye ne-FAK futhi ishicilele imiphumela yocwaningo kumajenali ezemfundo adumile. Idatha yomtholampilo yangaphambi kwesikhathi ku-IN10018 ibonise ukuphepha nokusebenza kwayo ezinhlotsheni eziningi zesimila, futhi imiphumela yakamuva yocwaningo kanye nedatha yangaphambi komtholampilo ibonise ukuthi i-IN10018 ingasebenza futhi ekwelashweni okuhlangene. Kulindeleke ukuthi inqobe umgoqo we-fibrosis ehambisana nesimila futhi ithuthukise ukuzivikela kwasendaweni, futhi ngenxa yalokho inamandla okusebenza njenge-molecule ebalulekile ekuxhumaneni nezindlela zokwelapha ezihlukene ezihlanganisa i-immunotherapy, i-chemotherapy, nokwelashwa okuhlosiwe.

I-InxMed imise uhlelo lomhlaba wonke lokuthuthukiswa komtholampilo lwe-IN10018. Izivivinyo zemitholampilo eziqhubekayo e-US nase-China zenzelwe umdlavuza we-ovarian ongazweli i-platinum, i-NRAS mutant metastatic melanoma, umdlavuza webele ophindwe kathathu, umdlavuza wekhanda nentamo, umdlavuza we-pancreatic, nezinye izimila eziqinile ezingakatholakali ukwelashwa okusebenzayo.